CS DIAGNOSTICS (CSDX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2025, filed Nov 13, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CSDX SEC filings page.
This page shows CS DIAGNOSTICS CORP (CSDX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
CS DIAGNOSTICS CORP does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
CS DIAGNOSTICS CORP generated $23K in revenue in Q3 2025. This represents an increase of 189.4% from the same quarter a year earlier.
CS DIAGNOSTICS CORP reported a net loss of $182 in Q3 2025. This represents a decrease of 134.0% from the same quarter a year earlier.
CS DIAGNOSTICS CORP earned $0.00 per diluted share (EPS) in Q3 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Not reported for Q3 2025.
Cash & Balance Sheet
CS DIAGNOSTICS CORP held $13 in cash as of Q3 2025; no long-term debt figure is on record for that period.
Not reported for Q3 2025.
Not reported for Q3 2025.
Margins & Returns
CS DIAGNOSTICS CORP's operating margin was -0.8% in Q3 2025, reflecting core business profitability. This is down 7.5 percentage points from the same quarter a year earlier.
CS DIAGNOSTICS CORP's net profit margin was -0.8% in Q3 2025, showing the share of revenue converted to profit. This is down 7.5 percentage points from the same quarter a year earlier.
CS DIAGNOSTICS CORP's quarterly ROE was 0.0% in Q3 2025: one quarter's net income over shareholder equity, not annualized.
Not reported for Q3 2025.
Capital Allocation
CS DIAGNOSTICS CORP reported no research and development spending in Q3 2025.
Not reported for Q3 2025.
Not reported for Q3 2025.
CSDX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA, Interest Expense, Income Tax.
CSDX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Current Liabilities, Non-Current Liabilities, Long-Term Debt.
CSDX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Current Ratio, Debt-to-Equity, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| CS DIAGNOSTICS CORP CSDX | FY2024 | N/A | $761 | N/A | $1.8M | — |
| GUIDED THERAPEUTCS INC GTHP | FY2025 | $767K | -$3.2M | N/A | $12.7M | — |
| BIOTRICITY INC BTCY | FY2026 | $16.0M | -$2.4M | -15.0% | N/A | — |
Where CS DIAGNOSTICS CORP Ranks
Frequently Asked Questions
Is CS DIAGNOSTICS CORP profitable?
Yes, CS DIAGNOSTICS CORP (CSDX) reported a net income of $761 in fiscal year 2024.
What is CS DIAGNOSTICS CORP's return on equity (ROE)?
CS DIAGNOSTICS CORP (CSDX) has a return on equity of 0.0% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What are CS DIAGNOSTICS CORP's total assets?
CS DIAGNOSTICS CORP (CSDX) had $499.4M in total assets as of fiscal year 2024, including both current and long-term assets.
What is CS DIAGNOSTICS CORP's liabilities-to-equity ratio?
CS DIAGNOSTICS CORP (CSDX) had a liabilities-to-equity ratio of 0.00 as of fiscal year 2024, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2024, because the filing data we hold for that year carries no long-term debt figure.
What is CS DIAGNOSTICS CORP's return on assets (ROA)?
CS DIAGNOSTICS CORP (CSDX) had a return on assets of 0.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is CS DIAGNOSTICS CORP's P/E ratio?
CS DIAGNOSTICS CORP (CSDX) has no price-to-earnings ratio at the moment: outside the range published as a multiple (on $761 net income, FY2024). The market capitalization is $1.8M as of Oct 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is CS DIAGNOSTICS CORP's price-to-sales ratio?
CS DIAGNOSTICS CORP (CSDX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $1.8M as of Oct 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.